𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial

✍ Scribed by D. Binder; H. Schweisfurth; C. Grah; C. Schäper; B. Temmesfeld-Wollbrück; G. Siebert; N. Suttorp; T. Beinert

Publisher
Springer
Year
2006
Tongue
English
Weight
340 KB
Volume
60
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multicenter, randomized, Phase II stud
A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma
✍ Filippo De Marinis; Fabrizio Nelli; Marco Lombardo; Francesco Ferraú; Santi Barb 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the activity and toxicity of combined cisplatin, etoposide, and gemcitabine (PEG) and combined cisplatin plus gemcitabine (PG) in previously untreated patients with extensive‐stage and poor‐prognosis limited‐stage small‐cell lun

Weekly docetaxel versus docetaxel/gemcit
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer : A randomized phase 3 trial of the Minnie Pearl Cancer Research Network
✍ John D. Hainsworth; David R. Spigel; Cindy Farley; Dianna L. Shipley; James D. B 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

## Abstract ## BACKGROUND. The aim of this study was to compare the efficacy of single‐agent weekly docetaxel with the combination of docetaxel and gemcitabine in elderly and/or poor performance status patients with advanced nonsmall cell lung cancer (NSCLC). ## METHODS. Previously untreated pat